Media ReleasesINOVIQ

View All INOVIQ News


INOVIQ Key Manufacturing Agreement to Advance SubB2M tests


* INOVIQ has executed a Master Manufacturing Agreement with MP Biomedicals for production of the SubB2M protein for the Company’s SubB2M-based tests
* INOVIQ’s SubB2M technology detects the pan-cancer biomarker Neu5Gc found at elevated levels in multiple human cancers
* SubB2M-based tests are in-development for multiple uses including monitoring breast and ovarian cancers, and for a general health panel
* MP Biomedicals is a global supplier of life science and diagnostic products
* Agreement with MP Biomedicals enables production of cGMP protein for commercial SubB2M tests and represents a key milestone for INOVIQ  

Melbourne, Australia, 2 May 2022: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) is pleased to announce that it has executed a Master Manufacturing Agreement with MP Biomedicals, a global supplier of life science and diagnostic products, for the contract manufacture of INOVIQ’s proprietary SubB2M protein.  

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.